Dusseldorf - Delayed Quote EUR

Merck KGaA (MRK.DU)

115.20

+0.30

+(0.26%)

At close: May 30 at 7:32:31 PM GMT+2

ASCO25: Merck KGaA’s ADC shows safety and tolerability in colorectal cancer trial

The Phase Ib study has helped Merck KGaA to determine the optimal dose for Phase II studies.

Clinical Trials Arena 21 hours ago

MRK.DE

GLDAF
ASCO25: Merck KGaA to seek approval of TGCT drug after Phase III success

The data for Merck KGaA's TGCT drug has been released ahead of a presentation at ASCO 2025 meeting.

Clinical Trials Arena 2 days ago

GLDAF

MRK.DE
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.

Zacks 4 days ago

MRK.DE
Queens of influence: Meet the women shaping Europe’s future

In its 28th year, the annual MPW list recognizes 100 women leading major global companies. This year, 21 listees are at the helm of European companies.

Fortune 8 days ago

BTGOF

MRK.DE

SW.PA
Merck KGaA’s lupus drug to advance to Phase III despite mixed data

While cohort A met the primary endpoint among other endpoints in the Phase II trial, cohort B failed to meet its primary endpoint.

Clinical Trials Arena 9 days ago

MRK.DE
Merck KGaA (ETR:MRK) Is Posting Promising Earnings But The Good News Doesn’t Stop There

The market seemed underwhelmed by the solid earnings posted by Merck KGaA ( ETR:MRK ) recently. We have done some...

Simply Wall St. 9 days ago

MKGAF

MKKGY
Merck KGaA (MKGAF) Q1 2025 Earnings Call Highlights: Strong Growth Amidst Challenges

Merck KGaA (MKGAF) reports robust revenue and EBITDA growth, while navigating macroeconomic headwinds and adjusting guidance for 2025.

GuruFocus.com 15 days ago

MRK.DE
Merck KGaA First Quarter 2025 Earnings: EPS Misses Expectations

Merck KGaA ( ETR:MRK ) First Quarter 2025 Results Key Financial Results Revenue: €5.28b (up 3.1% from 1Q 2024). Net...

Simply Wall St. 15 days ago

MKGAF

MKKGY
Merck KGaA Shares Slide After Outlook Cut on Tariff, Currency Risks

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and foreign-exchange headwinds.

The Wall Street Journal 16 days ago

MKGAF

MKKGY
MKKGY vs. ZTS: Which Stock Is the Better Value Option?

MKKGY vs. ZTS: Which Stock Is the Better Value Option?

Zacks 29 days ago

ZTS

MRK.DE
Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 29 days ago

MRK.DE
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The acquisition price translates to an equity value of around $3.9 billion and an enterprise value of $3.4 billion (3.0 billion euros), based on SpringWorks' cash position of $461.9 million as of December 31, 2024. As per media reports in February, Merck Germany reacted to press reports and confirmed advanced

Benzinga last month

MRK

MRK.DE
Temu, Tesla prices, Merck KGaA deal: Trending Tickers

Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV prices in Canada and Merck KGaA (MRK) seeks to acquire SpringWorks Therapeutics (SWTX) in a $3.9 billion deal. Catalysts host Madison Mills and Ritholtz Wealth Management chief market strategist Callie Cox weigh in on these top stocks. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Yahoo Finance Video last month

MKGAF

MKKGY

TSLA
5 Things to Know Before the Stock Market Opens

News of the day for April 28, 2025

Investopedia last month

MRK.DE

DLVEY

AAPL
Merck KGaA strikes $3.9bn deal for SpringWorks

The deal follows months of market speculation and gives Merck access to two FDA-approved therapies.

Pharmaceutical Technology last month

MRK.DE

GLDAF
Merck KGaA to buy biotech SpringWorks for $3.9B

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

BioPharma Dive last month

MRK.DE
Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal

Germany’s Merck agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

The Wall Street Journal last month

SWTX

MKGAF

MKKGY
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.

Investopedia last month

MRK.DE
SpringWorks Therapeutics to Be Acquired by Germany's Merck in $3.9 Billion Deal

SpringWorks Therapeutics (SWTX) stock rose early Monday after the biopharmaceutical company agreed t

PREMIUM
MT Newswires last month

MRK.DE
Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents. The deal came at a price tag about 20% lower than what analysts expected due to lack of other serious bidders and the overall devaluation of the U.S. biotech sector. Policy and regulatory changes for the healthcare sector in the United States, including massive layoffs at the U.S. Food and Drug Administration that approves new drugs, have been stalling large life science deals in what had been expected to be a stellar year for mergers and acquisitions.

Reuters last month

MRK.DE

Performance Overview

Return	MRK.DU	DAX P (^GDAXI)
YTD	-15.80%	+20.53%
1-Year	-28.43%	+29.74%
3-Year	-32.78%	+64.64%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck KGaA (MRK.DU)

ASCO25: Merck KGaA’s ADC shows safety and tolerability in colorectal cancer trial

ASCO25: Merck KGaA to seek approval of TGCT drug after Phase III success

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

Queens of influence: Meet the women shaping Europe’s future

Merck KGaA’s lupus drug to advance to Phase III despite mixed data

Merck KGaA (ETR:MRK) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Merck KGaA (MKGAF) Q1 2025 Earnings Call Highlights: Strong Growth Amidst Challenges

Merck KGaA First Quarter 2025 Earnings: EPS Misses Expectations

Merck KGaA Shares Slide After Outlook Cut on Tariff, Currency Risks

MKKGY vs. ZTS: Which Stock Is the Better Value Option?

Are Investors Undervaluing Merck KGaA (MKKGY) Right Now?

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

Temu, Tesla prices, Merck KGaA deal: Trending Tickers

5 Things to Know Before the Stock Market Opens

Merck KGaA strikes $3.9bn deal for SpringWorks

Merck KGaA to buy biotech SpringWorks for $3.9B

Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

SpringWorks Therapeutics to Be Acquired by Germany's Merck in $3.9 Billion Deal

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Performance Overview